Figure 4
Xenograft model of disseminated i.p. tumors. Anti-FAP-F19-∆CD28/CD3ζ or anti-NY-ESO-1-T1-∆CD28/CD3ζ re-directed T cells were co-injected i.p. with 1*106 HT1080FAP-luc tumor cells at an effector to target ratio of 5:1. HT1080FAP-luc tumor cells were recorded by bioluminescence imaging in the same mouse at the indicated days starting day 4 after cell injection (a). A total of 11 mice per experimental setting were treated with re-directed T cells from 2 different donors (donor 1: 6 mice per group, donor 2: 5 mice per group). The median survival of mice was determined by Kaplan-Meier analysis (b). Significance between cohorts was determined by log rank test.